Your browser is no longer supported. Please, upgrade your browser.
Settings
CBLI Cleveland BioLabs, Inc. daily Stock Chart
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own64.39% Shs Outstand11.35M Perf Week-4.59%
Market Cap27.89M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.58M Perf Month36.84%
Income-2.40M PEG- EPS next Q- Inst Own7.20% Short Float9.45% Perf Quarter31.65%
Sales1.10M P/S25.36 EPS this Y26.70% Inst Trans116.23% Short Ratio0.41 Perf Half Y235.48%
Book/sh-0.37 P/B- EPS next Y- ROA-102.50% Target Price- Perf Year37.75%
Cash/sh0.11 P/C18.60 EPS next 5Y- ROE63.00% 52W Range0.50 - 5.00 Perf YTD245.51%
Dividend- P/FCF- EPS past 5Y-19.00% ROI52.50% 52W High-58.40% Beta0.98
Dividend %- Quick Ratio1.70 Sales past 5Y-21.40% Gross Margin- 52W Low316.00% ATR0.34
Employees7 Current Ratio1.70 Sales Q/Q0.00% Oper. Margin- RSI (14)49.90 Volatility7.81% 17.47%
OptionableNo Debt/Eq- EPS Q/Q32.90% Profit Margin- Rel Volume0.22 Prev Close2.08
ShortableYes LT Debt/Eq- EarningsMay 27 BMO Payout- Avg Volume1.28M Price2.08
Recom- SMA20-1.21% SMA507.17% SMA20034.88% Volume0 Change0.00%
Jan-24-14Downgrade Oppenheimer Outperform → Perform
Mar-21-13Initiated Cantor Fitzgerald Buy $4
Dec-06-12Initiated Oppenheimer Outperform $3
Dec-04-12Initiated Burrill Institutional Research Mkt Outperform $4
Feb-02-11Initiated Wedbush Outperform $10
Oct-13-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
Sep-17-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
Jul-21-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
Sep-29-09Initiated Rodman & Renshaw Mkt Outperform $8
Jun-03-20 04:05PM  
Jun-01-20 08:30AM  
May-15-20 09:00AM  
Jan-28-20 07:53AM  
07:12AM  
Nov-18-19 06:58AM  
Nov-14-19 04:30PM  
Oct-04-19 10:25AM  
Aug-20-19 01:40PM  
Aug-14-19 08:30AM  
Jun-12-19 10:30AM  
May-25-19 08:15AM  
May-15-19 08:30AM  
Mar-07-19 08:15AM  
Feb-07-19 11:58AM  
Dec-14-18 02:22PM  
Dec-06-18 09:31AM  
Nov-23-18 07:20AM  
Nov-14-18 07:30AM  
Oct-05-18 01:24PM  
Aug-14-18 05:15PM  
04:45PM  
Aug-06-18 05:00PM  
Jun-22-18 03:12PM  
Jun-12-18 07:30AM  
May-31-18 04:18PM  
May-15-18 08:00AM  
Apr-17-18 02:37PM  
Mar-28-18 05:05PM  
Mar-06-18 08:00AM  
Feb-21-18 04:28PM  
Feb-09-18 02:02PM  
Jan-01-18 02:45PM  
Dec-29-17 11:40AM  
Dec-22-17 04:55PM  
Dec-13-17 12:55PM  
Dec-01-17 07:00AM  
Nov-30-17 01:36PM  
Nov-29-17 08:17AM  
Nov-22-17 08:40PM  
Nov-15-17 11:38AM  
Nov-14-17 08:15AM  
Nov-08-17 04:49PM  
Oct-26-17 10:23AM  
Oct-11-17 11:17AM  
Sep-19-17 05:11PM  
Sep-18-17 12:02PM  
Sep-11-17 03:57PM  
Aug-11-17 08:00AM  
Aug-04-17 07:26PM  
Jul-12-17 02:18PM  
Jun-26-17 03:32PM  
Jun-16-17 03:31PM  
Jun-05-17 02:06PM  
Jun-02-17 10:27AM  
May-15-17 07:30AM  
Apr-20-17 08:00AM  
Apr-19-17 02:14PM  
Apr-18-17 07:30AM  
Apr-17-17 07:36AM  
07:30AM  
Apr-11-17 05:00PM  
Apr-07-17 04:05PM  
Mar-17-17 12:04PM  
Mar-14-17 02:58PM  
Feb-28-17 01:04PM  
Feb-22-17 04:21PM  
04:15PM  
Dec-07-16 11:24AM  
Nov-15-16 11:56AM  
Nov-14-16 07:31AM  
07:30AM  
Oct-11-16 08:46AM  
08:45AM  
Sep-28-16 09:41AM  
Sep-12-16 10:38AM  
Aug-30-16 11:00AM  
Aug-19-16 12:43PM  
Aug-18-16 10:43AM  
Aug-15-16 08:42AM  
08:30AM  
Jul-22-16 04:22PM  
Jul-21-16 06:05AM  
Jul-19-16 12:08PM  
Jul-12-16 04:25PM  
09:00AM  
May-17-16 12:26PM  
May-16-16 07:30AM  
May-12-16 02:40PM  
May-06-16 05:55PM  
Apr-15-16 03:05PM  
Apr-04-16 07:30AM  
Mar-16-16 02:50PM  
02:00PM  
Feb-23-16 05:04PM  
Feb-22-16 10:35AM  
07:30AM  
Feb-09-16 07:30AM  
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.